Prevention and/or Treatment of Neurodegenerative Disorders
AssigneeUlive Enterprises Limited
InventorJeremy Turnbull
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition for use in the prevention and/or treatment of a neurodegenerative disorder comprising a compound comprised of one or more disaccharide units, the or each disaccharide unit comprising a uronate moiety linked to a glucosamine moiety, wherein the 2-O atom of the uronate moiety is substituted with a hydrogen atom, the 6-O atom of the glucosamine moiety is substituted with a sulphate group and the 2-N atom of the glucosamine moiety is substituted with an atom or group other than a sulphate group. The composition is particularly preferred for use in the prevention and/or treatment of Alzheimer's disease.
Claims37
A compound for use in the prevention and/or treatment of a neurodegenerative disorder comprising one or more disaccharide units comprising a uronate moiety linked to a glucosamine moiety, wherein the 2-O atom of the uronate moiety is substantially substituted with a hydrogen atom, the 6-O atom of the glucosamine moiety is substantially substituted with a sulphate group and the 2-N atom of the glucosamine moiety is substituted with an atom or group other than a sulphate group.
(canceled)
(canceled)
(canceled)
A method for preventing and/or treating a neurodegenerative disorder comprising administering to a subject a therapeutic amount of a compound comprising one or more disaccharide units comprising a uronate moiety linked to a glucosamine moiety, wherein the 2-O atom of the uronate moiety is substantially substituted with a hydrogen atom, the 6-O atom of the glucosamine moiety is substantially substituted with a sulphate group and the 2-N atom of the glucosamine moiety is substituted with an atom or group other than a sulphate group.
(canceled)
A pharmaceutical composition for use in the prevention and/or treatment of a neurodegenerative disorder comprising a compound comprising one or more disaccharide units comprising a uronate moiety linked to a glucosamine moiety, wherein the 2-O atom of the uronate moiety is substantially substituted with a hydrogen atom, the 6-O atom of the glucosamine moiety is substantially substituted with a sulphate group and the 2-N atom of the glucosamine moiety is substituted with an atom or group other than a sulphate group.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.